Menu Search
Equities

Zhaoke Ophthalmology Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
6622:HKG.HZ

Zhaoke Ophthalmology Ltd

Actions
  • Price (HKD)3.46
  • Today's Change0.00 / 0.00%
  • Shares traded42.50k
  • 1 Year change+94.38%
  • Beta1.4473
Data delayed at least 15 minutes, as of Feb 16 2026 03:54 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Zhaoke Ophthalmology Ltd is an investment holding company principally engaged in the development, manufacturing and marketing of ophthalmic drugs and products. The product pipelines primarily include NVK002 (Atropine) for myopia, CsA Ophthalmic Gel for DED and TAB014 (Bevacizumab) for wAMD. The products are primarily uses to treat eye diseases across both the front and the back of the eye, including dry eye disease (DED), myopia, presbyopia, wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), glaucoma and corneal epithelial dysfunction (CED). The Company conducts its business in the domestic market and overseas markets.

  • Revenue in HKD (TTM)40.05m
  • Net income in HKD-315.22m
  • Incorporated2020
  • Employees270.00
  • Location
    Zhaoke Ophthalmology LtdNo. 1 Meide 3rd Road, Pearl RiverIndustrial Park, Nansha DistrictGUANGZHOU ChinaCHN
  • Phone+86 2 039062888
  • Websitehttps://www.zkoph.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.